GlassScriptPhysician profile
Mohammad Arastu
NPI 1285604488
$2,483.86
in general payments reported to CMS, 2019-2025
19 companies · $407 in 2025
The $407 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.56 · 2020: $246 · 2021: $465 · 2022: $415 · 2023: $495 · 2024: $406 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,267 · Education: $41.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,267.15 |
| Education | $41.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $605.05 | 2020-2024 | Afrezza |
| Corcept Therapeutics | $359.17 | 2020-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $332.78 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Abbvie INC. | $278.76 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $161.46 | 2019-2023 | Somatuline Depot |
| Kyowa Kirin, INC. | $160.19 | 2023-2024 | Crysvita |
| Lilly USA, LLC | $140.52 | 2019-2025 | Mounjaro, Jardiance |
| Amryt Pharma Holdings LTD | $110.48 | 2023 | Mycapssa, Myalept |
| Abbott Laboratories | $78.10 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $52.97 | 2020-2023 | |
| Recordati_rare_diseases_inc. | $42.37 | 2025 | Isturisa |
| Amgen INC. | $33.84 | 2025 | Tepezza |
| Madrigal Pharmaceuticals | $24.58 | 2025 | Rezdiffra |
| Chiesi USA, INC. | $24.32 | 2025 | Mycapssa |
| Alexion Pharmaceuticals, INC. | $20.11 | 2023 | Strensiq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $18.02 | 2024 | Omnipod |
| Aimmune Therapeutics, INC. | $14.83 | 2025 | Zenpep |
| Pfizer INC. | $14.48 | 2021 | |
| Allergan, INC. | $11.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Arastu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.